- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00719407
Neonatal Erythropoietin in Asphyxiated Term Newborns (NEAT)
November 7, 2012 updated by: Yvonne Wu, University of California, San Francisco
Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial
The purpose of this study is to determine the safety and pharmacokinetics of moderate to high doses of erythropoietin in newborn infants with birth asphyxia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Newborn infants with birth asphyxia are at high risk of death or long-term neurologic disability; yet therapies for birth asphyxia are currently limited.
Erythropoietin (Epo) is a FDA-approved drug that is an effective neuroprotective agent in animal models of birth asphyxia.
This is a phase I dose finding multi-center trial that will test the safety and pharmacokinetics of Epo in human infants with birth asphyxia.
The long-term objectives of the proposed research are to reduce mortality and to decrease the risk of long-term disabilities in infants who survive beyond the newborn period.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 1 day (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 36 weeks gestational age
- Perinatal depression (low Apgar score, need for resuscitation)
- Moderate to severe encephalopathy
Exclusion Criteria:
- Specific aEEG findings
- Intrauterine growth restriction
- Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH infection
- Microcephaly
- Infant older than 23.5 hours of age at the time of consent
- Infant judged by an attending physician to be likely to die due to the severity of illness
- Polycythemia
- Hypertension
- No in-dwelling line
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
All enrolled patients will be in this single arm, who will receive experimental drug treatment.
|
250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serious adverse event
Time Frame: 14 days of life
|
14 days of life
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters
Time Frame: 1 to 11 days of life
|
1 to 11 days of life
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Shankaran S. Outcomes of hypoxic-ischemic encephalopathy in neonates treated with hypothermia. Clin Perinatol. 2014 Mar;41(1):149-59. doi: 10.1016/j.clp.2013.10.008.
- Rogers EE, Bonifacio SL, Glass HC, Juul SE, Chang T, Mayock DE, Durand DJ, Song D, Barkovich AJ, Ballard RA, Wu YW. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol. 2014 Nov;51(5):657-62. doi: 10.1016/j.pediatrneurol.2014.08.010. Epub 2014 Aug 27.
- Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC, Juul SE. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012 Oct;130(4):683-91. doi: 10.1542/peds.2012-0498. Epub 2012 Sep 24.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
July 17, 2008
First Submitted That Met QC Criteria
July 17, 2008
First Posted (Estimate)
July 21, 2008
Study Record Updates
Last Update Posted (Estimate)
November 9, 2012
Last Update Submitted That Met QC Criteria
November 7, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H9299-32566-01
- Thrasher 02827-0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxic-ischemic Encephalopathy
-
Johns Hopkins UniversityUniversity of MarylandCompletedEncephalopathy, Hypoxic-IschemicUnited States
-
Sajjad RahmanUnknownSevere Hypoxic Ischemic Encephalopathy | Moderate Hypoxic Ischemic EncephalopathyTurkey, Egypt, Malaysia, Qatar, Saudi Arabia, United Arab Emirates
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEncephalopathy, Hypoxic IschemicItaly
-
Cliniques universitaires Saint-Luc- Université...Active, not recruitingEncephalopathy, Hypoxic-IschemicBelgium
-
University Hospital, GrenobleUnknownIschemic-Hypoxic EncephalopathyFrance
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Navy General Hospital, BeijingDaping Hospital and the Research Institute of Surgery of the Third Military... and other collaboratorsUnknownHypoxic-Ischemic EncephalopathyChina
-
Istanbul Training and Research HospitalCompletedHypoxic-Ischemic EncephalopathyTurkey
-
University of FloridaAmerican Heart AssociationCompleted
Clinical Trials on erythropoietin
-
University of CambridgeHoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)CompletedAneurysmal Subarachnoid HemorrhageUnited Kingdom
-
Bundang CHA HospitalLG Life SciencesCompleted
-
Chugai PharmaceuticalCompletedChemotherapy Induced Anemia
-
Angde Biotech Pharmaceutical Co., Ltd.Recruiting
-
NICHD Neonatal Research NetworkNational Center for Research Resources (NCRR)CompletedAnemia, Neonatal | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States
-
Fatih Sultan Mehmet Training and Research HospitalDr. Lutfi Kirdar Kartal Training and Research HospitalCompleted
-
Shenyang Sunshine Pharmaceutical Co., LTD.Unknown
-
VA Office of Research and DevelopmentTerminatedAtherosclerosis | Anemia | CKD | CardiovascularUnited States
-
Tianjin SinoBiotech Ltd.Completed
-
Shenzhen Second People's HospitalRecruiting